Case number 2020-2071
Sanofi-Aventis Deutschland v. Mylan Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 22, 2022 | 110 | Mandate issued to the United States Patent and Trademark Office. Service as of this date by the Clerk of Court. [832672] [MVH] [Entered: 02/22/2022 02:19 PM] (1) |
| Jan 2, 2022 | 0 | SANOFI-AVENTIS DEUTSCHLAND v. MYLAN PHARMACEUTICALS, INC. [OPINION] [nonprecedential] (0) |
| Dec 29, 2021 | 108 | OPINION filed for the court by Dyk, Circuit Judge; Clevenger, Circuit Judge and Taranto, Circuit Judge. Nonprecedential Per Curiam Opinion. Service as of this date by the Clerk of Court. [821656] [MVH] [Entered: 12/29/2021 09:55 AM] (4) |
| Dec 29, 2021 | 109 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [821658] [MVH] [Entered: 12/29/2021 09:56 AM] (2) |
| Dec 6, 2021 | 107 | Submitted after ORAL ARGUMENT to Panel: Dyk, Circuit Judge; Clevenger, Circuit Judge and Taranto, Circuit Judge.Arguing counsel: Ms. Sarah M. Sternlieb for Sanofi-Aventis Deutschland GmbH and Douglas H. Carsten for Mylan Pharmaceuticals, Inc.Oral Argument Audio available here. [816410] [JCP] [Entered: 12/06/2021 01:10 PM] (0) |
| Nov 8, 2021 | 104 | NOTICE OF NON-COMPLIANCE: The submission of Sanofi-Aventis Deutschland GmbH, Response to Notice of Oral Argument [102], [103], is not in compliance with the rules of this court (see attached). Compliant document due 11/16/2021. Service as of this date by the Clerk of Court. [810850] [MJL] [Entered: 11/08/2021 01:22 PM] (1) |
| Nov 8, 2021 | 105 | Response to notice of oral argument from Intervenor Andrew Hirshfeld. Service: 11/08/2021 by email. [810897] [20-2071] [Daniel Kazhdan] [Entered: 11/08/2021 02:44 PM] (1) |
| Nov 8, 2021 | 106 | Corrected Response to notice of oral argument from Appellant Sanofi-Aventis Deutschland GmbH. Service: 11/08/2021 by email. [810913] [20-2071] [Sarah Sternlieb] [Entered: 11/08/2021 03:00 PM] (3) |
| Nov 2, 2021 | 102 | Response to notice of oral argument from Appellant Sanofi-Aventis Deutschland GmbH. Service: 11/02/2021 by email. [809738] [20-2071]. This document is non-compliant. See Doc. No. [104]. [Adam Banks] [Entered: 11/02/2021 02:32 PM] (3) |
| Nov 2, 2021 | 103 | Corrected Response to notice of oral argument from Appellant Sanofi-Aventis Deutschland GmbH. Service: 11/02/2021 by email. [809776] [20-2071]. This document is non-compliant. See Doc. No. [104]. [Adam Banks] [Entered: 11/02/2021 03:21 PM] (3) |
| Oct 25, 2021 | 100 | NOTICE OF NON-COMPLIANCE: The submission of Mylan Pharmaceuticals, Inc., Response to Notice of Oral Argument [99], is not in compliance with the rules of this court (see attached). Compliant document due 11/01/2021. Service as of this date by the Clerk of Court. [807841] [MJL] [Entered: 10/25/2021 08:40 AM] (1) |
| Oct 25, 2021 | 101 | Corrected Response to notice of oral argument from Appellee Mylan Pharmaceuticals, Inc.. Service: 10/25/2021 by email. [807926] [20-2071] [Douglas Carsten] [Entered: 10/25/2021 11:11 AM] (3) |
| Oct 22, 2021 | 99 | Response to notice of oral argument from Appellee Mylan Pharmaceuticals, Inc.. Service: 10/22/2021 by email. [807711] [20-2071]. This document is non-compliant. See Doc. No. [100]. [Douglas Carsten] [Entered: 10/22/2021 02:13 PM] (3) |
| Oct 21, 2021 | 98 | NOTICE OF ORAL ARGUMENT. Panel: 2112B. Case scheduled December 6, 2021. Response to Notice of Oral Argument due: 11/15/2021. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [807404] [JCP] [Entered: 10/21/2021 04:50 PM] (2) |
| Sep 9, 2021 | 96 | ORDER filed granting motion to reschedule argument filed by Appellant Sanofi-Aventis Deutschland GmbH in 20-1871 [795901-2], in 20-2066 [795903-2], in 20-2071 [92] and in 21-1262 [795906-2]. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [798113] [20-1871, 20-2066, 20-2071, 21-1262] [MVH] [Entered: 09/09/2021 04:05 PM] (5) |
| Sep 9, 2021 | 97 | The following conflict dates submitted by Sanofi-Aventis Deutschland GmbH have been accepted by the court: 11/01/2021, 11/02/2021, 11/03/2021, 11/04/2021, 11/05/2021. [798125] [MVH] [Entered: 09/09/2021 04:16 PM] (0) |
| Sep 3, 2021 | 95 | REPLY of Appellant Sanofi-Aventis Deutschland GmbH to response [93]. Service: 09/03/2021 by email. [797131] [20-2071] [Adam Banks] [Entered: 09/03/2021 12:05 PM] (7) |
| Sep 2, 2021 | 93 | RESPONSE of Appellee Mylan Pharmaceuticals, Inc. to Doc No. [92]. Service: 09/02/2021 by email. [797035] [20-2071] [Elham Steiner] [Entered: 09/02/2021 06:45 PM] (5) |
| Sep 2, 2021 | 94 | Response to notice of oral argument from Appellee Mylan Pharmaceuticals, Inc.. Service: 09/02/2021 by email. [797039] [20-2071] [Douglas Carsten] [Entered: 09/02/2021 06:55 PM] (3) |
| Aug 30, 2021 | 92 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH to reschedule argument. Service: 08/30/2021 by email. [795905] [20-2071] [Adam Banks] [Entered: 08/30/2021 11:00 AM] (9) |
| Aug 20, 2021 | 91 | NOTICE OF ORAL ARGUMENT. Panel: 2110H. Case scheduled October 6, 2021. Response to Notice of Oral Argument due: 09/15/2021. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [794477] [MJL] [Entered: 08/20/2021 04:58 PM] (2) |
| Aug 9, 2021 | 90 | Notice from Intervenor Andrew Hirshfeld regarding conflicts with oral argument. None. Service: 08/09/2021 by email. [791343] [20-2071] [Daniel Kazhdan] [Entered: 08/09/2021 10:48 AM] (0) |
| Aug 6, 2021 | 89 | Notice from Appellant Sanofi-Aventis Deutschland GmbH regarding conflicts with oral argument. Service: 08/06/2021 by email. [791032] [20-2071] [Adam Banks] [Entered: 08/06/2021 10:16 AM] (1) |
| Aug 3, 2021 | 88 | Notice from Appellee Mylan Pharmaceuticals, Inc. regarding conflicts with oral argument. None. Service: 08/03/2021 by email. [790325] [20-2071] [Richard Torczon] [Entered: 08/03/2021 01:43 PM] (0) |
| Aug 2, 2021 | 87 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [789822] [EKD] [Entered: 08/02/2021 10:17 AM] (1) |
| Jul 29, 2021 | 86 | ORDER filed lifting stay. This appeal will be scheduled for oral argument in due course. The Clerk of Court shall transmit this order to the merits panel assigned to this appeal. (Per Curiam). Service as of this date by the Clerk of Court. [789379] [LMS] [Entered: 07/29/2021 12:10 PM] (2) |
| Jul 19, 2021 | 85 | RESPONSE of Appellee Mylan Pharmaceuticals, Inc. to Doc No. [82], [82], [82]. Service: 07/19/2021 by email. [786999] [20-2071] [Richard Torczon] [Entered: 07/19/2021 11:33 AM] (10) |
| Jul 16, 2021 | 84 | RESPONSE of Intervenor Andrew Hirshfeld to Doc. No. [82], [82], [82]. Service: 07/16/2021 by email. [786751] [20-2071] [Daniel Kazhdan] [Entered: 07/16/2021 12:21 PM] (4) |
| Jul 7, 2021 | 83 | RESPONSE of Appellant Sanofi-Aventis Deutschland GmbH to Doc No. [82], [82], [82]. Service: 07/07/2021 by email. [784661] [20-2071] [Adam Banks] [Entered: 07/07/2021 05:49 PM] (7) |
| Jun 23, 2021 | 82 | ORDER filed. Within 14 days from the date of this order, the parties that raised an Appointments Clause challenge shall file a brief, not to exceed 10 pages double-spaced, explaining how they believe their cases should proceed in light of Arthrex. Responses from the other parties, including the United States Patent and Trademark Office, subject to the same length restrictions, are due within 14 days thereafter. All deadlines and proceedings are stayed. Service as of this date by the Clerk of Court. [782107] [20-1874, 20-1886, 20-1890, 20-1927, 20-1930, 20-1946, 20-1947, 20-1948, 20-1961, 20-1992, 20-1994, 20-2001, 20-2059, 20-2066, 20-2068, 20-2069, 20-2071] [MJL] [Entered: 06/23/2021 05:04 PM] (2) |
| Jun 14, 2021 | 81 | The following conflict dates submitted by Adam Banks for Sanofi-Aventis Deutschland GmbH have been accepted by the court: 08/02/2021, 08/03/2021, 08/04/2021, 08/05/2021, 08/06/2021, 08/30/2021, 08/31/2021, 09/01/2021, 09/02/2021, 09/03/2021. [779996] [MVH] [Entered: 06/14/2021 09:50 AM] (0) |
| Jun 7, 2021 | 80 | Corrected Entry of appearance for Douglas H. Carsten; Adam Burrowbridge as counsel for Appellee Mylan Pharmaceuticals, Inc.. Service: 06/07/2021 by email. [778698] [20-2071] [Richard Torczon] [Entered: 06/07/2021 10:11 AM] (2) |
| Jun 3, 2021 | 79 | 6 paper copies of Doc. No. [65] received from Appellee Mylan Pharmaceuticals, Inc.. [778517] [VDW] [Entered: 06/04/2021 11:17 AM] (0) |
| Jun 2, 2021 | 78 | NOTICE OF NON-COMPLIANCE: The submissions of Appellee Mylan Pharmaceuticals Inc. in 20-1871, 20-2066, and 20-2071, and Appellees Biocon Ltd., Biocon Research Ltd., Biocon S.A., Biocon Sdn.Bhd, and Mylan GmbH in 21-1262, Entries of Appearance [777225-2], [777227-2], [73], [777233-2], are not in compliance with the rules of this court (see attached). Compliant documents are due on 06/09/2021. Service as of this date by the Clerk of Court. [778143] [20-1871, 20-2066, 20-2071, 21-1262] [EKD] [Entered: 06/02/2021 02:35 PM] (1) |
| Jun 1, 2021 | 76 | Notice from Appellant Sanofi-Aventis Deutschland GmbH regarding conflicts with oral argument. Service: 06/01/2021 by email. [777940] [20-2071] [Adam Banks] [Entered: 06/01/2021 05:06 PM] (4) |
| May 28, 2021 | 77 | 6 paper copies of Doc. No. [68], [67], [50] received from Appellant Sanofi-Aventis Deutschland GmbH. [778033] [VDW] [Entered: 06/02/2021 10:01 AM] (0) |
| May 27, 2021 | 74 | Notice from Appellee Mylan Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 05/27/2021 by email. [777419] [20-2071] [Richard Torczon] [Entered: 05/27/2021 02:04 PM] (4) |
| May 27, 2021 | 75 | 6 paper copies of Doc. No. [43] received from Intervenor Andrew Hirshfeld. [777454] [VDW] [Entered: 05/27/2021 03:41 PM] (0) |
| May 26, 2021 | 73 | Entry of appearance for Douglas H. Carsten; Adam Burrowbridge as counsel for Appellee Mylan Pharmaceuticals, Inc.. Service: 05/26/2021 by email. [777229] [20-2071] This document is non-compliant. See Doc No. [78] [Richard Torczon] [Entered: 05/26/2021 01:14 PM] (2) |
| May 25, 2021 | 71 | Notice to counsel: The Clerk's Office directs that outstanding paper copies of all briefs and appendices in this case must be submitted on or before June 2, 2021. See Administrative Order No. 20-01 (Mar. 20, 2020). [777010] [EKD] [Entered: 05/25/2021 02:47 PM] (0) |
| May 25, 2021 | 72 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [777011] [EKD] [Entered: 05/25/2021 02:48 PM] (1) |
| May 18, 2021 | 68 | MODIFIED ENTRY: APPENDIX FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 05/18/2021 by email. [775771] --[Edited 05/25/2021 by EKD - compliance review complete] [Adam Banks] [Entered: 05/18/2021 03:55 PM] (628) |
| May 18, 2021 | 69 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellant Sanofi-Aventis Deutschland GmbH. Service: 05/18/2021 by email. [775772] [20-2071] [Adam Banks] [Entered: 05/18/2021 03:59 PM] (5) |
| May 18, 2021 | 70 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellant Sanofi-Aventis Deutschland GmbH. Service: 05/18/2021 by email. [775774] [20-2071] [Adam Banks] [Entered: 05/18/2021 04:00 PM] (5) |
| May 11, 2021 | 66 | Notice of Correction to Doc No. [63] for Appellant Sanofi-Aventis Deutschland GmbH. Service: 05/11/2021 by email. [774293] [20-2071] [Adam Banks] [Entered: 05/11/2021 01:34 PM] (3) |
| May 11, 2021 | 67 | MODIFIED ENTRY: CORRECTED REPLY BRIEF FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 05/11/2021 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [774294] --[Edited 05/11/2021 by EKD - compliance review complete] [Adam Banks] [Entered: 05/11/2021 01:36 PM] (36) |
| May 5, 2021 | 65 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED by Appellee Mylan Pharmaceuticals, Inc. Service: 05/05/2021 by email. [773142]--[Edited 05/06/2021 by EKD - compliance review complete] [Richard Torczon] [Entered: 05/05/2021 02:40 PM] (51) |
| May 4, 2021 | 64 | ORDER granting [60] Mylan's motion. Appeal No. 2020-2139 is withdrawn. The revised official caption is reflected above. Each side shall bear its own costs as to Appeal No. 2020-2139.; denying as moot [61] Sanofi's motion to extend time in 2020-2071.; (see order for details) The Clerk of Court will forward a copy of this order to the merits panel assigned to this appeal.; issuing mandate as to 2020-2139 only. Service as of this date by the Clerk of Court. [772718] [20-2071, 20-2139] [LMS] [Entered: 05/04/2021 10:04 AM] (3) |
| Apr 26, 2021 | 62 | Certificate of Interest for Appellant Sanofi-Aventis Deutschland GmbH. Service: 04/26/2021 by email. [771316] [20-2071] [Adam Banks] [Entered: 04/26/2021 11:22 PM] (3) |
| Apr 26, 2021 | 63 | REPLY BRIEF FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 04/26/2021 by email. [771317] [20-2071] This document has been corrected. See Doc No. [67] [Adam Banks] [Entered: 04/26/2021 11:23 PM] (54) |
| Apr 23, 2021 | 60 | MOTION of Cross-Appellant Mylan Pharmaceuticals, Inc. to voluntarily dismiss appeal pursuant to FRAP 42(b). Service: 04/23/2021 by email. [771006] [20-2071] [Richard Torczon] [Entered: 04/23/2021 05:16 PM] (6) |
| Apr 23, 2021 | 61 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH to extend time. Service: 04/23/2021 by email. [771029] [20-2071] [Adam Banks] [Entered: 04/23/2021 07:42 PM] (10) |
| Apr 9, 2021 | 59 | **TEXT ONLY** ORDER granting motion to extend time to file brief [58] filed by Appellant Sanofi-Aventis Deutschland GmbH. The reply brief is due 04/26/2021. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [767719] [EKD] [Entered: 04/09/2021 11:52 AM] (0) |
| Apr 8, 2021 | 58 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH to extend the time to 04/26/2021 to file brief. Service: 04/08/2021 by email. [767526] [20-2071] [Adam Banks] [Entered: 04/08/2021 01:43 PM] (10) |
| Mar 29, 2021 | 57 | **TEXT ONLY** ORDER granting motion to withdraw attorney Douglas H. Carsten [52] filed by Cross-Appellant Mylan Pharmaceuticals, Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [765285] [EKD] [Entered: 03/29/2021 09:12 AM] (0) |
| Mar 26, 2021 | 55 | Corrected Entry of appearance for Richard Torczon; Steffen N. Johnson as counsel for Cross-Appellant Mylan Pharmaceuticals, Inc.. Service: 03/26/2021 by email. [765053] [20-2071] [Richard Torczon] [Entered: 03/26/2021 01:41 PM] (0) |
| Mar 26, 2021 | 56 | ORDER The motion [45] is granted to the extent that Mylan may include the declaration in the joint appendix and may cite to the document in its briefs. The relevance of the document, however, is left to the merits panel assigned to these appeals. A copy of this order and the motion papers shall be transmitted to the merits panel. (Per Curiam). Service as of this date by the Clerk of Court. [765191] [NL] [Entered: 03/26/2021 05:13 PM] (0) |
| Mar 25, 2021 | 54 | NOTICE OF NON-COMPLIANCE: The submission of Cross-Appellant Mylan Pharmaceuticals, Inc., Entry of Appearance [53], is not in compliance with the rules of this court (see attached). Compliant document is due on 04/01/2021. Service as of this date by the Clerk of Court. [764808] [EKD] [Entered: 03/25/2021 04:27 PM] (0) |
| Mar 24, 2021 | 52 | MOTION of Cross-Appellant Mylan Pharmaceuticals, Inc. to withdraw counsel Douglas H. Carsten. Service: 03/24/2021 by email. [764523] [20-2071] [Richard Torczon] [Entered: 03/24/2021 02:29 PM] (0) |
| Mar 24, 2021 | 53 | Entry of appearance for Richard Torczon; Steffen N. Johnson as counsel for Cross-Appellant Mylan Pharmaceuticals, Inc. Service: 03/24/2021 by email. [764525] [20-2071] This document is non-compliant. See Doc No. [54] [Richard Torczon] [Entered: 03/24/2021 02:31 PM] (0) |
| Mar 5, 2021 | 49 | Amended Certificate of Interest for Appellant Sanofi-Aventis Deutschland GmbH. Service: 03/05/2021 by email. [760550] [20-2071] [Adam Banks] [Entered: 03/05/2021 06:00 PM] (0) |
| Mar 5, 2021 | 50 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 03/05/2021 by email. [760551] --[Edited 03/08/2021 by EKD - compliance review complete] [Adam Banks] [Entered: 03/05/2021 06:03 PM] (0) |
| Mar 5, 2021 | 51 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED by Cross-Appellant Mylan Pharmaceuticals, Inc. Service: 03/05/2021 by email. [760571] --[Edited 03/08/2021 by EKD - compliance review complete] [Richard Torczon] [Entered: 03/05/2021 08:37 PM] (0) |
| Mar 4, 2021 | 48 | Amended Certificate of Interest for Cross-Appellant Mylan Pharmaceuticals, Inc.. Service: 03/04/2021 by email. [760209] [20-2071] [Richard Torczon] [Entered: 03/04/2021 06:40 PM] (0) |
| Mar 4, 2021 | 47 | MODIFIED ENTRY: CORRECTED INTERVENOR BRIEF FILED by Intervenor Andrew Hirshfeld. Service: 03/04/2021 by email. [760014] --[Edited 03/05/2021 by EKD - compliance review complete] [Daniel Kazhdan] [Entered: 03/04/2021 11:44 AM] (15) |
| Mar 3, 2021 | 46 | NOTICE OF NON-COMPLIANCE: The submissions of Appellant Sanofi-Aventis Deutschland GmbH, Corrected Opening Brief [41], Cross-Appellant Mylan Pharmaceuticals, Inc., Response Brief [44], and Intervenor Andrew Hirshfeld, Intervenor Brief [43], are not in compliance with the rules of this court (see attached). Compliant documents are due on 03/10/2021. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [759772] [EKD] [Entered: 03/03/2021 12:08 PM] (2) |
| Mar 2, 2021 | 42 | Entry of appearance for Brian Racilla; Kakoli Caprihan as counsel for Intervenor Andrew Hirshfeld. Service: 03/02/2021 by email. [759377] [20-2071] [Brian Racilla] [Entered: 03/02/2021 07:31 AM] (2) |
| Mar 2, 2021 | 43 | INTERVENOR BRIEF FILED by Intervenor Andrew Hirshfeld. Service: 03/02/2021 by email. [759454] [20-2071] This document is non-compliant. See Doc No. [46] [Daniel Kazhdan] [Entered: 03/02/2021 11:41 AM] (15) |
| Mar 2, 2021 | 44 | RESPONSE BRIEF FILED by Cross-Appellant Mylan Pharmaceuticals, Inc.. Service: 03/02/2021 by email. [759686] [20-2071] This document is non-compliant. See Doc No. [46] [Richard Torczon] [Entered: 03/02/2021 09:34 PM] (69) |
| Mar 2, 2021 | 45 | MOTION of Cross-Appellant Mylan Pharmaceuticals, Inc. to correct or supplement Brief [44]. Service: 03/02/2021 by email. [759687] [20-2071] [Richard Torczon] [Entered: 03/02/2021 09:39 PM] (10) |
| Feb 26, 2021 | 41 | CORRECTED OPENING BRIEF FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 02/26/2021 by email. [758862] [20-2071] This document is non-compliant. See Doc No. [46] [Adam Banks] [Entered: 02/26/2021 10:15 AM] (163) |
| Feb 25, 2021 | 40 | NOTICE OF NON-COMPLIANCE: The submission of Appellant Sanofi-Aventis Deutschland GmbH, Opening Brief [25], is not in compliance with the rules of this court (see attached). Compliant document is due on 03/04/2021. Service as of this date by the Clerk of Court. [758592] [EKD] [Entered: 02/25/2021 11:15 AM] (1) |
| Feb 4, 2021 | 39 | Docketing Statement for the Intervenor Andrew Hirshfeld. Service: 02/04/2021 by email. [753942] [20-2071] [Daniel Kazhdan] [Entered: 02/04/2021 10:47 AM] (2) |
| Jan 27, 2021 | 38 | ORDER granting [748890-2] [748891-2] [32] the motions. The revised official captions are reflected above. Appeal No. 2020-2144 is withdrawn. Each side shall bear its own costs with respect to Appeal No. 2020-2144. ISSUED AS A MANDATE (as to Appeal No. 2020-2144 only): January 27, 2021. Service as of this date by the Clerk of Court. [751964] [20-1871, 20-2029, 20-2032, 20-2033, 20-2034, 20-2159, 20-2066, 20-2068, 20-2069, 20-2071, 20-2144] [LMS] [Entered: 01/27/2021 08:28 AM] (5) |
| Jan 22, 2021 | 37 | Official caption revised to reflect Andrew Hirshfeld, Performing the Functions and Duties of the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, as Intervenor (see attached). Service as of this date by the Clerk of Court. [751257] [EKD] [Entered: 01/22/2021 04:37 PM] (2) |
| Jan 21, 2021 | 36 | ORDER granting motions [737383-2], [737385-2], [20], & [737390-2] to the extent that the appeals shall be considered companion cases and assigned to the same merits panel. Sanofi’s motion to dismiss [8] is denied. The parties are directed to address the standing issues in their briefs. Pfizer’s motion [12] is granted to the extent provided herein. ECF Nos. 14 and 15 in Appeal Nos. 2020-2071, -2139, -2144 are accepted for filing. The Director of the United States Patent and Trademark Office is added as an intervenor. The revised official captions are reflected in the order. (See order for briefing details) Service as of this date by the Clerk of Court. [750712] [20-1871, 20-2029, 20-2159, 20-2066, 20-2071, 21-1262] [NL] [Entered: 01/21/2021 04:36 PM] (6) |
| Jan 19, 2021 | 35 | Notice of Correction to Doc No. [33] for Cross-Appellant Mylan Pharmaceuticals, Inc.. Service: 01/19/2021 by email. [750065] [20-2071] [Richard Torczon] [Entered: 01/19/2021 11:57 AM] (38) |
| Jan 15, 2021 | 33 | Letter from Cross-Appellant Mylan Pharmaceuticals, Inc. Citation of Supplemental Authority FRAP 28(j).. Service: 01/15/2021 by email. [749878] [20-2071] [Richard Torczon] [Entered: 01/15/2021 04:04 PM] (2) |
| Jan 15, 2021 | 34 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellant Mylan Pharmaceuticals, Inc.. Service: 01/15/2021 by email. [749893] [20-2071] [Richard Torczon] [Entered: 01/15/2021 04:46 PM] (35) |
| Jan 12, 2021 | 32 | MODIFIED ENTRY: MOTION of Cross-Appellant Pfizer, Inc. to withdraw party, Pfizer, Inc., as a party to this appeal and to voluntarily dismiss appeal pursuant to FRAP 42(b). Service: 01/12/2021 by email. [748893]--[Edited 01/13/2021 by JAL to correct relief] [Thomas Meloro] [Entered: 01/12/2021 05:17 PM] (7) |
| Jan 6, 2021 | 30 | Notice of Intervention pursuant to the provisions of 35 USC Section 143 from the Director of the United States Patent and Trademark Office. Service: 01/06/2021 by email. [747439] [20-2071] [Daniel Kazhdan] [Entered: 01/06/2021 03:27 PM] (2) |
| Jan 6, 2021 | 31 | Entry of appearance for Daniel Kazhdan; Thomas W. Krause; Farheena Y. Rasheed; Mary L. Kelly as counsel for Intervenor - Director U.S. Patent and Trademark Office. Service: 01/06/2021 by email. [747442] [20-2071] [Daniel Kazhdan] [Entered: 01/06/2021 03:29 PM] (2) |
| Dec 22, 2020 | 29 | Entry of appearance for Thomas J. Meloro; Charles B. Klein; Jovial Wong; Dan H. Hoang; Michael W. Johnson; Devon W. Edwards as counsel for Cross-Appellant Pfizer, Inc.. Service: 12/22/2020 by email. [744780] [20-2071] [Thomas Meloro] [Entered: 12/22/2020 02:27 PM] (2) |
| Dec 7, 2020 | 28 | ORDER Notice of Sanofi's constitutional challenges [739051-2] [739052-2] [26] are hereby certified to the Attorney General. No later than 30 days from the date of filing of this order, the Attorney General is directed to inform this court whether the United States intends to intervene in these appeals. The briefing schedules are stayed. Service as of this date by the Clerk of Court. [740564] [20-1871, 20-2066, 20-2071] [LMS] [Entered: 12/07/2020 09:36 AM] (4) |
| Dec 2, 2020 | 27 | REPLY of Appellant Sanofi-Aventis Deutschland GmbH to response [23]. Service: 12/02/2020 by email. [739756] [20-2071] [Adam Banks] [Entered: 12/02/2020 04:31 PM] (9) |
| Nov 30, 2020 | 24 | Certificate of Interest for Appellant Sanofi-Aventis Deutschland GmbH. Service: 11/30/2020 by email. [738990] [20-2071] [Anish Desai] [Entered: 11/30/2020 08:23 PM] (3) |
| Nov 30, 2020 | 25 | OPENING BRIEF FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 11/30/2020 by email. [739048] [20-2071] This document is non-compliant. See Doc No. [40] [Adam Banks] [Entered: 11/30/2020 11:11 PM] (163) |
| Nov 30, 2020 | 26 | Notice from Appellant Sanofi-Aventis Deutschland GmbH Constitutional Question. Service: 11/30/2020 by email. [739053] [20-2071] [Adam Banks] [Entered: 11/30/2020 11:42 PM] (6) |
| Nov 25, 2020 | 23 | RESPONSE of Cross-Appellant Mylan Pharmaceuticals, Inc. to the motion [20]. Service: 11/25/2020 by email. [738518] [20-2071] [Richard Torczon] [Entered: 11/25/2020 05:30 PM] (13) |
| Nov 23, 2020 | 21 | REPLY of Appellant Sanofi-Aventis Deutschland GmbH to response [13], response [14]. Service: 11/23/2020 by email. [737893] [20-2071] [Adam Banks] [Entered: 11/23/2020 09:10 PM] (20) |
| Nov 23, 2020 | 22 | Confidential SANOFI'S REPLY IN FURTHER SUPPORT OF ITS MOTION TO DISMISS CROSS-APPEALS filed by Appellant Sanofi-Aventis Deutschland GmbH corresponding to Doc. No. [21]. Service: 11/23/2020 by email. [737894] [20-2071] [Adam Banks] [Entered: 11/23/2020 09:19 PM] (0) |
| Nov 20, 2020 | 20 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH DESIGNATE APPEALS AS COMPANION CASES AND TO SET COORDINATED BRIEFING SCHEDULE. Service: 11/20/2020 by email. [737387] [20-2071] [Adam Banks] [Entered: 11/20/2020 03:35 PM] (8) |
| Nov 9, 2020 | 19 | ORDER granting motion to extend time to file [17] filed by Appellant Sanofi-Aventis Deutschland GmbH. Service as of this date by the Clerk of Court. [734461] [LMS] [Entered: 11/09/2020 11:05 AM] (2) |
| Nov 5, 2020 | 17 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH to extend time. Service: 11/05/2020 by email. [733845] [20-2071] [Adam Banks] [Entered: 11/05/2020 11:22 AM] (10) |
| Nov 5, 2020 | 18 | ORDER granting motion to extend time to file brief [16] filed by Appellant Sanofi-Aventis Deutschland GmbH. The opening brief is due 11/30/2020. Service as of this date by the Clerk of Court. [733938] [LMS] [Entered: 11/05/2020 01:33 PM] (2) |
| Nov 2, 2020 | 13 | RESPONSE of Cross-Appellant Mylan Pharmaceuticals, Inc. to the motion [8]. Service: 11/02/2020 by email. [732996] [20-2071] [Richard Torczon] [Entered: 11/02/2020 03:40 PM] (77) |
| Nov 2, 2020 | 14 | RESPONSE of Cross-Appellant Pfizer, Inc. to the motion for other relief [8]. Service: 11/02/2020 by email. [733083] [20-2071] [Charles Klein] [Entered: 11/02/2020 05:53 PM] (206) |
| Nov 2, 2020 | 15 | Confidential Opposition to Sanofi's Motion to Dismiss Cross-Appeals filed by Cross-Appellant Pfizer, Inc. corresponding to Doc. No. [14]. Service: 11/02/2020 by email. [733090] [20-2071] [Charles Klein] [Entered: 11/02/2020 06:07 PM] (0) |
| Nov 2, 2020 | 16 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH to extend the time to 11/30/2020 to file brief. Service: 11/02/2020 by email. [733134] [20-2071] [Adam Banks] [Entered: 11/02/2020 10:32 PM] (11) |
| Oct 27, 2020 | 12 | MOTION of Cross-Appellant Pfizer, Inc. to modify the protective order, to waive confidentiality requirements. Service: 10/27/2020 by email. [731906] [20-2071] [Charles Klein] [Entered: 10/27/2020 08:31 PM] (13) |
| Oct 16, 2020 | 11 | ORDER granting motion to extend time [9] filed by Cross-Appellants. The response to motion to dismiss is due on or before 11/02/2020. Service as of this date by the Clerk of Court. [729463] [NL] [Entered: 10/16/2020 03:06 PM] (2) |
| Oct 14, 2020 | 10 | Amended Entry of appearance for Charles B. Klein; Jovial Wong; Dan H. Hoang; Zachary B. Cohen as counsel for Cross-Appellant Pfizer, Inc.. Service: 10/14/2020 by email. [728581] [20-2071] [Charles Klein] [Entered: 10/14/2020 12:50 PM] (2) |
| Oct 9, 2020 | 9 | MOTION of Cross-Appellants Mylan Pharmaceuticals, Inc. and Pfizer, Inc. to extend time. Service: 10/09/2020 by email. [728018] [20-2071] [Douglas Carsten] [Entered: 10/09/2020 06:37 PM] (9) |
| Oct 8, 2020 | 8 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH Dismiss Cross-Appeals. Service: 10/08/2020 by email. [727706] [20-2071] [Adam Banks] [Entered: 10/08/2020 04:03 PM] (143) |
| Sep 25, 2020 | 5 | ORDER consolidating appeals 20-2071, 20-2139, and 20-2144. The stays of the briefing schedules are lifted. The opening briefs for each group of appeals are due within 60 days from the filing date of the last-filed Certified List within each group. Service as of this date by the Clerk of Court. [724600] [20-2071, 20-2139, 20-2144] [LMN] [Entered: 09/25/2020 04:22 PM] (4) |
| Sep 25, 2020 | 6 | Note to File: The following cases are consolidated: 20-2071 Lead with 20-2139 and 20-2144 Member Cases. The parties must file all documents in the lead appeal only. [724603] [20-2071, 20-2139, 20-2144] [LMN] [Entered: 09/25/2020 04:32 PM] (0) |
| Sep 25, 2020 | 7 | Note to File: The following cases shall be considered companion cases and assigned to the same merits panel: 20-1871, 20-2066, and 20-2071. [724604] [20-1871, 20-2066, 20-2071] [LMN] [Entered: 09/25/2020 04:36 PM] (0) |
| Sep 10, 2020 | 4 | Certified list for 20-2029, 20-2032, 20-2071, 20-2139, and 20-2144 received. Service: 09/08/2020 by email. [720624] [20-1871, 20-2029, 20-2032, 20-2071, 20-2139, 20-2144] [EKD] [Entered: 09/10/2020 09:15 AM] (279) |
| Jul 31, 2020 | 2 | ORDER consolidating appeals 20-1871, 20-2029, 20-2032, and 20-2071. The Certified Lists in Appeal Nos. 2020-2029, 20-2032, and 20-2071 are due no later than September 8, 2020. The opening brief is due within 60 days from the filing date of the last-filed of the Certified Lists. Service as of this date by the Clerk of Court. [711620] [20-1871, 20-2029, 20-2032, 20-2071] [EKD] [Entered: 07/31/2020 01:47 PM] (2) |
| Jul 31, 2020 | 3 | Note to File: The following cases are consolidated: 20-1871 Lead with 20-2029, 20-2032, and 20-2071 Consolidated Member Cases. The parties must file all documents in the lead appeal only. [711622] [20-1871, 20-2029, 20-2032, 20-2071] [EKD] [Entered: 07/31/2020 01:56 PM] (0) |
| Jul 27, 2020 | 1 | Appeal docketed. Received: 07/23/2020. [710332] Entry of Appearance is due on 08/10/2020. Certificate of Interest is due on 08/10/2020. Docketing Statement is due on 08/10/2020. Certified List is due on 09/08/2020. [EKD] [Entered: 07/27/2020 03:45 PM] (79) |
